Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

NCT06248606 is registered in ClinicalTrials.gov with Ryan Gentzler, MD as lead sponsor.

NCT NCT06248606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06248606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Lead sponsor
Ryan Gentzler, MD
Phase
Phase 2
Overall status
Recruiting
Start date
August 6, 2024
Completion date
February 25, 2028
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12c, non small cell lung cancer, nsclc